ClinicalTrials.gg
RecruitingNCT06398106HELIOSUpdated Mar 4, 2026

Proactive TDM Versus Standard Use of Biologics in Psoriasis

A Phase 4 interventional study of Proactive TDM-based dosing of secukinumab and Proactive TDM-based dosing of ixekizumab in Psoriasis Vulgaris, sponsored by University Hospital, Ghent. Recruiting at 15 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by University Hospital, Ghent · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Planned enrollment
16th of 54
210 · median 124
Started
2024
with 1 other
Phase 4
17 of 54
4 open now
Registered
52nd of 54
by date

Among the 54 studies testing secukinumab in Psoriasis, this one is the 16th largest by planned enrollment, is one of 2 that started in 2024, is one of 17 in phase 4, and was the 52nd registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

Biologics are effective agents for the treatment of psoriasis. The newest generation of biologics block interleukin 17 and 23. Physicians always prescribe these drugs in a fixed dose, but this may lead to under- and overdosing in some patients. Underdosing may lead to inadequate response or loss of response over time. Overdosage, on the other hand, can lead to higher risk of side effects and higher costs for the healthcare system. In daily clinical practice, physicians often tackle this real-world issue by blind trial- and- error dose modifications or switching to another biologic. In this study, we want to rationalize these dose modifications and optimize dosing based on the drug concentrations, measured in the blood of the patient (i.e. therapeutic drug monitoring). Depending on the drug concentration, the interval between injections will be lengthened or shortened with the aim to reach the required drug concentration to reach the best clinical result. The trial will be conducted in 14 Belgian hospitals where patients will be divided into 2 study groups: a group that will be advised on the dosing scheme of their biologic based on the measured drug concentration and a group that continues dosing as in daily clinical practice. We will monitor if the clinical response and quality of life remains stable. With this study, we will track drug concentrations as we believe that they can guide dosing of biologics and we hope to achieve better safety, lower healthcare expenses and higher patients' treatment satisfaction while striving for the best clinical response.

Read the detailed description

Rationale:

Biologics are effective agents for the treatment of psoriasis. The newest generation of biologics block interleukin 17 and 23. Physicians always prescribe these drugs in a fixed dose, but this may lead to under- and overdosing in some patients. Underdosing may lead to inadequate response or loss of response over time. Overdosage, on the other hand, can lead to higher risk of side effects and higher costs for the healthcare system. In daily clinical practice, physicians often tackle this real-world issue by blind trial- and- error dose modifications or switching to another biologic. In this study, we want to rationalize these dose modifications and optimize dosing based on the drug concentrations, measured in the blood of the patient (i.e. therapeutic drug monitoring).

Objectives: The primary goal is to assess if proactive TDM is non-inferior compared to standard of care with respect to sustained disease control, defined as an absolute PASI ≤ 2 OR a delta PASI from baseline ≥ 50% during at least 80% of all 3-monthly study visits over a period of 18 months, in patients with moderate to severe psoriasis treated with novel biologics (secukinumab, ixekizumab or guselkumab). Secondary goals are:

To compare proactive TDM to standard of care with respect to disease activity, quality of life, treatment satisfaction and costs of treatment (cost-effectiveness) To identify baseline predictors for sustained disease control. To evaluate the cost-effectiveness of proactive TDM To evaluate the safety of proactive TDM.

Study design: A multicentre, pragmatic, randomised, controlled, non-inferiority trial.

Study population:

Patients with moderate-to-severe psoriasis, treated with secukinumab or ixekizumab (IL-17 inhibitors) or guselkumab (IL-23 inhibitor) in daily clinical practice for at least 6 months on standard dosing (maintenance phase). A total of 210 patients will be randomized (1:1) to the intervention group (TDM based dosing) or continuation of usual care.

Intervention: Stepwise treatment modifications based on drug levels: if the drug level is below/above the target, the dose of the biologic will be increased/decreased by stepwise interval shortening/lengthening - first modified by 33% and then 50% increase or decrease. If the target is still not reached at the next study visit, the dosing interval will be shortened or prolonged with one additional week at each additional visit until the target is reached.

In case the dosing regimen shifts from dose increase to dose decrease or vice versa, the dosing interval will be shortened or prolonged with one additional week at each additional visit until the target is reached.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

Keywords

  • Therapeutic drug monitoring
  • Biologics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults; aged 18 years or older
  2. Documented diagnosis of psoriasis (predominantly type vulgaris; based on clinical diagnosis) by an accredited dermatologist
  3. Patients must be currently treated with secukinumab, ixekizumab or guselkumab ≥ 6 months according to the standard dosing scheme.
  4. The subject signs and dates a written form and any required privacy authorization prior to the initiation of any study procedures

Exclusion criteria

Exclusion Criteria:

  1. Another indication than plaque psoriasis as the main indication for biologic use (e.g. receives biologic for rheumatoid arthritis as the main indication)
  2. Concomitant use of systemic other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc)
  3. Severe comorbidities with short life-expectancy (e.g. metastasized tumour) or uncontrolled PsA at inclusion/baseline
  4. Presumed inability to follow the study protocol
  5. Active pregnancy wish
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • No intervention
    Standard dosing of biologics

    Patients will receive biological therapy according to standard clinical practice. Secukinumab, ixekizumab and guselkumab will be administered according to standard dosing regimen. Adjustments in doses and intervals, or biological switch according to clinical parameters or at the physicians' discretion are considered as standard clinical practice. Investigators will not have access to information on levels of the drug or antidrug antibodies and no decision tree will be provided to guide treatment adjustments.

  • Experimental
    Proactive TDM based dosing

    Stepwise treatment modifications based on drug levels: if the drug level is below/above the target the dose of the biologic will be increased/decreased by stepwise interval shortening/lengthening - first modified by 33% and then 50% increase or decrease. If the target is still not reached at the next study visit, the dosing interval will be shortened or prolonged with one additional week at each additional visit until the target is reached. In case the dosing regimen shifts from dose increase to dose decrease or vice versa, the dosing interval will be shortened or prolonged with one additional week at each additional visit until the target is reached.

    Drug: Proactive TDM-based dosing of secukinumab · Drug: Proactive TDM-based dosing of ixekizumab · Drug: Proactive TDM-based dosing of guselkumab

Interventions

  • DrugSecukinumabStudies of SecukinumabSecukinumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Maintenance/normal dose is 300 mg/4 weeks or 300 mg/ month First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks. Further dose reduction steps: prolongation with 1 additional week First dose escalation step: 300 mg/3 weeks Second dose escalation step: 300 mg/2 weeks Further dose escalation step: shortening with 1 additional week

    Also known as: Cosentyx

  • DrugIxekizumabStudies of IxekizumabIxekizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks Further dose reduction steps: prolongation with 1 additional week First dose escalation step: 80 mg/3 weeks Second dose escalation step: 80 mg/2 weeks Further dose escalation step: shortening with 1 additional week

    Also known as: Taltz

  • DrugGuselkumabStudies of GuselkumabGuselkumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks. Further dose reduction steps: prolongation with 1 additional week First dose escalation step: 100 mg/6 weeks Second dose escalation step: 100 mg/4 weeks Further dose escalation step: shortening with 1 additional week

    Also known as: Tremfya

06

What researchers measure

Primary outcomes

  1. Non-inferiority of sustained disease control

    Sustained disease control, defined as an absolute PASI ≤ 2 OR a delta PASI from baseline ≥ 50% during at least 80% of all 12-weekly study visits over a period of 76 weeks.

    Time frame: 76 weeks

Secondary outcomes

  1. Psoriasis disease activity, measured with the Psoriasis Area and Severity Index (PASI) at each 12-weekly study visit.

    Change from baseline at week 76 in PASI score. The PASI measures disease activity. The scores ranges from 0 (skin lesion free) to 72 with higher scores indicating higher disease activity.

    Time frame: 76 weeks

  2. Dermatology-related quality of life as measured with the Dermatology Life Quality Index (DLQI-R) at each 12-weekly study visit.

    Change from baseline at week 76 in DLQI\_R score. The DLQI\_R measures QoL. The score ranges from 0 (no impact) to 30 (greatest impact) with higher scores indicating higher impact on quality of life.

    Time frame: 76 weeks

  3. Health status of participants, assessed by using the Short Form 36 (SF-36) version 2 questionnaire at every 12-weekly time point.

    Change from baseline at week 76 in SF-36 score. The SF-36 measures QoL. The score ranges from 0 (maximum disability) to 100 (no disability). In the field of dermatology, the SF36 has been proposed as the instrument of choice for evaluating QoL in a generic way by Both et al.. Although we acknowledge that the SF36 can be perceived as more difficult to fill in by the patients, comparison of QoL measures by Fernandez-Penas et al, showed that SF-36 was more sensitive than other instruments in detecting worse QoL in male patients. The minimal clinical important difference (MCID) for SF-36 is considered 10 units.

    Time frame: 76 weeks

  4. Whether participants will have serious adverse events (SAE) and adverse events of special interest (AEoSI) during the study period.

    AEoSI include, but are not limited to, * Occurrence of infusion reactions * Drug (biologic) Immunogenicity * Moderate-to severe infections * Newly diagnosis of cancer * New-onset of psoriatic arthritis * Joint complains

    Time frame: week 76

  5. Pharmacokinetics of the drugs of interest

    Drug concentrations of each included drug, measured in blood serum samples which will be collected from participants at each 12-weekly time point. The drug concentrations will be evaluated with an enzyme-linked immunosorbent assay (ELISA) and compared to the target/reference concentration. In the intervention group, these drug concentrations will guide the modification of the dosing interval (according to a predefined decision tree).

    Time frame: 76 weeks

  6. Immunogenicity of the drugs of interest

    Anti-drug antibody levels of each included drug, measured in blood serum samples which will be collected from participants at each 12-weekly time point.

    Time frame: 76 weeks

  7. Utilities, derived from EuroQoL 5 Dimensions (EQ-5D-5L) questionnaires, which will be measured at each 12-weekly time point.

    Utility scores will be used to calculate quality adjusted life years (QALYs) which are used to determine cost-effectiveness of the intervention.

    Time frame: 76 weeks

  8. Volumes of care, as measured with the iMTA Medical Consumption Questionnaire (MCQ) at each 12-weekly time point.

    The iMTA Medical Consumption Questionnaire (iMCQ) is an instrument for measuring medical consumption. The iMCQ includes questions related to frequently occurring contacts with health care providers. The iMCQ is a generic questionnaire and will be used to calculate direct medicals costs and non-medical costs.

    Time frame: 76 weeks

07

Study locations

10 of 15 sites recruiting
  • AZ Sint-Jan
    Bruges, Belgium
    Recruiting
    • Els Wittouck · Contact
    • Els Wittouck, Dr. · Principal investigator
  • CHU Saint-Pierre
    Brussels, 1000, Belgium
    Recruiting
    • Jonathan Krygier · Contact
    • Jonathan Krygier, Dr. · Principal investigator
  • UCL Saint-Luc
    Brussels, Belgium
    Active, not recruiting

    Not enrolling at this site.

  • ULB Erasme
    Brussels, Belgium
    Not yet recruiting
    • Farida Benhadou · Contact
    • Farida Benhadou, Dr. · Principal investigator
  • UZ Brussel
    Brussels, Belgium
    Recruiting
    • Jan Gutermuth · Contact
    • Valerie Reynaert, Prof. · Principal investigator
  • Grand Hôpital de Charleroi
    Charleroi, Belgium
    Active, not recruiting

    Not enrolling at this site.

  • AZ Alma
    Eeklo, 9900, Belgium
    Recruiting
  • Dermatologiepraktijk huidziekten Geel
    Geel, Belgium
    Recruiting
    • Hugo Boonen, Dr. · Contact
    • Hugo Boonen, Dr. · Principal investigator
  • AZ Maria Middelares
    Ghent, Belgium
    Recruiting
    • Veerle Dhondt, Dr. · Contact
    • Veerle Dhondt, Dr. · Principal investigator
  • UZ Gent
    Ghent, Belgium
    Recruiting
    • Jo Lambert, Prof. · Contact
    • Jo Lambert, Prof. · Principal investigator
  • Clinique André Renard
    Herstal, Belgium
    Withdrawn

    Not enrolling at this site.

  • Dermatologie Handelskaai
    Kortrijk, Belgium
    Recruiting
    • Erwin Suys, Dr. · Contact
    • Erwin Suys, Dr. · Principal investigator
  • UZ Leuven
    Leuven, Belgium
    Recruiting
    • Tom Hillary, Dr. · Contact
    • Tom Hillary, Dr. · Principal investigator
  • CHU Liège
    Liège, Belgium
    Active, not recruiting

    Not enrolling at this site.

  • Dermatologie Maldegem
    Maldegem, Belgium
    Recruiting
    • Sven Lanssens, Dr. · Contact
    • Sven Lanssens, Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Mar 2028, 38 months after the start.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 38 months is above that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2024
First posted
May 3, 2024
StartActual
Dec 20, 2024
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2028
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06398106
Collaborators
Belgium Health Care Knowledge Centre
Responsible party
Sponsor
First posted
May 3, 2024
Start date
Dec 20, 2024
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Mar 4, 2026

Study contacts

Jo Lambert, Prof
Contact
jo.lambert@uzgent.be
093322298 ext. +32
Rani Soenen, Dr.
Contact
rani.soenen@uzgent.be
093326541 ext. +32
Jo Lambert, Prof.
principal investigator · University Hospital, Ghent

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Secukinumab · Ixekizumab · Guselkumab

Start the discussion